KAPA (Kairos Pharma) Net Margin %: 0.00% (As of Mar. 2026)


KAPA Kairos Pharma Ltd KAPA
15 GF Score
Price $0.38
View Full Analysis

What is Kairos Pharma Net Margin %?

Kairos Pharma KAPA +7.48% 15 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates KAPA with a GF Score™ of 15/100. Among 944 Biotechnology companies, Kairos Pharma ranks worse than 105932.1% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Kairos Pharma's Net Income for the three months ended in Mar. 2026 was $-1.65 Mil. Kairos Pharma's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Kairos Pharma's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Kairos Pharma's Net Margin % or its related term are showing as below:


KAPA's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.815
* Ranked among companies with meaningful Net Margin % only.

Kairos Pharma  (AMEX:KAPA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Kairos Pharma Net Margin % Related Terms

Kairos Pharma Net Margin % Historical Data

* Premium members only.

The historical data trend for Kairos Pharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kairos Pharma Net Margin % Chart

Kairos Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Kairos Pharma Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

KAPA vs IMNN, HCWB, CURX: Net Margin % Comparison

For the Biotechnology subindustry, Kairos Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kairos Pharma Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kairos Pharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Kairos Pharma's Net Margin % falls into.


KAPA
15GF Score
Kairos Pharma Ltd KAPA
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kairos Pharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Kairos Pharma's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-5.447/0
= %

Kairos Pharma's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.654/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Kairos Pharma (KAPA) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Kairos Pharma and its competitors. According to the industry distribution chart, Kairos Pharma ranks #999999 out of 944 companies in the Biotechnology industry.
Is Kairos Pharma's Net Margin % too high?
Kairos Pharma's current Net Margin % is 0.00%. Based on the distribution chart, Kairos Pharma ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kairos Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Kairos Pharma's Net Margin % compare to IMNN and HCWB?
According to the Biotechnology industry distribution chart, Kairos Pharma ranks #999999 out of 944 companies for Net Margin %. This places Kairos Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Kairos Pharma and its competitors. Kairos Pharma's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kairos Pharma stock overvalued right now?
Kairos Pharma (KAPA) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Kairos Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Kairos Pharma (KAPA), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kairos Pharma Business Description

Address 2355 Westwood Boulevard, No. 139, Los Angeles, CA, USA, 90064
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
15GF Score

Get the complete analysis for KAPA

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.38
Price